RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:623626

Paraneoplastic cerebellar degeneration

medium confidenceDisorder

Also known as: PCD · Paraneoplastic cerebellar ataxia · Rapidely progressive cerebellar syndrome · Subacute cerebellar degeneration

Publications

1,769

92.4th percentile

Trials

0

Interventional, condition-specific

Researchers

996

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

paraneoplastic cerebellar degeneration

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,769 matched papers (795 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 7 for broader category cerebellar degeneration

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,769

1,769 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,769 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

795 in the last 10 years · medium confidence · 92.4th percentile (publications denominator)

Phrase hits: 1,769 · MeSH hits: 26

Open Europe PMC search

Who's working on it?

996

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Desestret V6 papers · 2024

    From the Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon; French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon; University of Lyon, Université Claude Bernard Lyon 1; Department of Biopathology, Centre Leon Berard; INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon; Cancer Genomics Platform, Department of Translational Research, Centre Leon Berard; Synergie Lyon Cancer- Bioinformatics Platform-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon; and Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), France. virginie.desestret@chu-lyon.fr.

    Papers in Europe PMC
  2. 02
    Honnorat J6 papers · 2024

    From the Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon; French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon; University of Lyon, Université Claude Bernard Lyon 1; Department of Biopathology, Centre Leon Berard; INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon; Cancer Genomics Platform, Department of Translational Research, Centre Leon Berard; Synergie Lyon Cancer- Bioinformatics Platform-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon; and Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), France.

    Papers in Europe PMC
  3. 03
    Peter E5 papers · 2024

    From the Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon; French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon; University of Lyon, Université Claude Bernard Lyon 1; Department of Biopathology, Centre Leon Berard; INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon; Cancer Genomics Platform, Department of Translational Research, Centre Leon Berard; Synergie Lyon Cancer- Bioinformatics Platform-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon; and Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), France.

    Papers in Europe PMC
  4. 04
    Vedeler CA5 papers · 2024

    Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

    Papers in Europe PMC
  5. 05
    Graus F4 papers · 2026

    Neuroimmunology Program, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

    Papers in Europe PMC
  6. 06
    Mitoma H4 papers · 2024

    Department of Medical Education, Tokyo Medical University.

    Papers in Europe PMC
  7. 07
    Ren H4 papers · 2025

    Department of Neurology, Peking Union Medical College Hospital, Beijing, China.

    Papers in Europe PMC
  8. 08
    Wang J4 papers · 2026

    CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lincui Road, Chaoyang District, Beijing, 100101, China.

    Papers in Europe PMC
  9. 09
    Fan S3 papers · 2025

    Department of Neurology, Peking Union Medical College Hospital, Beijing, China.

    Papers in Europe PMC
  10. 10
    Greenlee JE3 papers · 2024

    Department of Neurology, University of Utah Health, 175 N. Medical Dr. E, Salt Lake City, UT, 84132, USA. john.greenlee@hsc.utah.edu.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial. 7 trials are registered for cerebellar degeneration, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

7 interventional trials matched cerebellar degeneration, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: cerebellar degeneration

7

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Paraneoplastic cerebellar degeneration" OR "Paraneoplastic cerebellar ataxia" OR "Rapidely progressive cerebellar syndrome" OR "Subacute cerebellar degeneration"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Paraneoplastic Cerebellar Degeneration

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Paraneoplastic cerebellar degeneration" OR "Paraneoplastic cerebellar ataxia" OR "Rapidely progressive cerebellar syndrome" OR "Subacute cerebellar degeneration" OR "paraneoplastic neurologic syndrome" OR "paraneoplastic syndrome" OR "cerebellar disorder"

Recall-expansion terms: paraneoplastic neurologic syndrome, paraneoplastic syndrome, cerebellar disorder

Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"cerebellar degeneration"

Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh, recall-expansion

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: PCD

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T19:11:48.781Z